Back to Stakeholders
Research, Drug Development & ManufacturingLead program: Pre-clinical

Empyrean Neuroscience

2 Drug Candidates

Empyrean Neuroscience is a New York-based biotech pioneering the use of genetic engineering of fungi and plants to develop novel neuroactive therapeutics for CNS disorders. Founded in 2019, the company launched with a $22M Series A from Spore Partners and uses CRISPR/Cas9 technology licensed from ERS Genomics to genetically modify Psilocybe cubensis, Tabernanthe iboga, and Cannabis sativa. Lead programmes include an encapsulated psilocybin mushroom drug product (IND-enabling studies) and DMT-based therapeutics for MDD, PTSD, and substance use disorders.

Drug Pipeline

2

Encapsulated psilocybin mushroom drug product

Psilocybin
Pre-clinical
Major Depressive Disorder (MDD)PTSD

Genetically engineered encapsulated psilocybin mushroom drug product; IND-enabling studies underway.

DMT (genetically engineered)

DMT
Discovery
Major Depressive Disorder (MDD)Substance Use Disorders (SUD)

DMT-based therapeutics from genetically engineered organisms; early discovery stage.

Quick Facts

Type
Private Biotech
Founded
2019
Lead Stage
Pre-clinical
Website
Visit